Current status of testing intervals for antiphospholipid syndrome testing: a 13-year retrospective national data analysis in South Korea.

Se-eun Koo, Jinyoung Hong, Kuenyoul Park, Seongsoo Jang
{"title":"Current status of testing intervals for antiphospholipid syndrome testing: a 13-year retrospective national data analysis in South Korea.","authors":"Se-eun Koo, Jinyoung Hong, Kuenyoul Park, Seongsoo Jang","doi":"10.1093/labmed/lmae025","DOIUrl":null,"url":null,"abstract":"OBJECTIVE\nTo assess the appropriateness of laboratory testing intervals and antiphospholipid syndrome (APS) incidence.\n\n\nMETHODS\nBetween January 2010 and August 2022, insurance claims data of patients with disease codes for other thrombophilia (D68.6) and APS (V253) were retrieved in South Korea. Patients who received antiphospholipid antibody tests more than twice were classified as having suspected APS. The interval between the first 2 antiphospholipid antibody tests was evaluated in the patients with suspected APS. Patients with suspected APS who received anticoagulants for >180 days were classified as having APS.\n\n\nRESULTS\nOverall, 8656 patients were classified as having suspected APS. The testing interval for the first 2 tests in patients with suspected APS was <6 and <12 weeks in 11.1% and 20.6% of cases, respectively, in 2010, gradually increasing to 21.0% and 35.4%, respectively, in 2021. Subsequently, 4344 patients were classified as having APS, with 65.0% being female. Only 330 patients were diagnosed with APS in 2021, down from 436 in 2020.\n\n\nCONCLUSION\nThis study showed a gradual increase in patients receiving antiphospholipid antibody testing with an inappropriate short-term interval, underscoring the need for laboratory stewardship to ensure an appropriate interval for APS testing.","PeriodicalId":17951,"journal":{"name":"Laboratory medicine","volume":"35 7","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laboratory medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/labmed/lmae025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

OBJECTIVE To assess the appropriateness of laboratory testing intervals and antiphospholipid syndrome (APS) incidence. METHODS Between January 2010 and August 2022, insurance claims data of patients with disease codes for other thrombophilia (D68.6) and APS (V253) were retrieved in South Korea. Patients who received antiphospholipid antibody tests more than twice were classified as having suspected APS. The interval between the first 2 antiphospholipid antibody tests was evaluated in the patients with suspected APS. Patients with suspected APS who received anticoagulants for >180 days were classified as having APS. RESULTS Overall, 8656 patients were classified as having suspected APS. The testing interval for the first 2 tests in patients with suspected APS was <6 and <12 weeks in 11.1% and 20.6% of cases, respectively, in 2010, gradually increasing to 21.0% and 35.4%, respectively, in 2021. Subsequently, 4344 patients were classified as having APS, with 65.0% being female. Only 330 patients were diagnosed with APS in 2021, down from 436 in 2020. CONCLUSION This study showed a gradual increase in patients receiving antiphospholipid antibody testing with an inappropriate short-term interval, underscoring the need for laboratory stewardship to ensure an appropriate interval for APS testing.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
抗磷脂综合征检测间隔的现状:韩国 13 年全国回顾性数据分析。
方法在 2010 年 1 月至 2022 年 8 月期间,在韩国检索了疾病代码为其他血栓性疾病(D68.6)和 APS(V253)的患者的保险理赔数据。接受抗磷脂抗体检测超过两次的患者被归类为疑似 APS 患者。对疑似 APS 患者首次接受两次抗磷脂抗体检测之间的间隔时间进行了评估。结果共有 8656 名患者被归类为疑似 APS 患者。2010 年,分别有 11.1% 和 20.6% 的疑似 APS 患者的前 2 次检测间隔<6 周和<12 周,到 2021 年,这一比例逐渐上升至 21.0% 和 35.4%。随后,4344 名患者被归类为 APS 患者,其中 65.0% 为女性。结论本研究显示,接受抗磷脂抗体检测的患者逐渐增多,但短期间隔不合适,这强调了实验室监管的必要性,以确保APS检测的合适间隔。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Robert L. Schmidt, MD, PhD, MBA (November 17, 1952-October 25, 2023) A 6-year-old boy with an atypical liver neoplasm harboring a novel RPS6KA3 variant. Evaluating direct amplification from viral transport medium for SARS-CoV-2 detection, strain typing, and angiotensin-converting enzyme genotyping and expression assays. Diagnostic value of pleural effusion Krebs von den Lungen-6 in malignant pleural effusion of patients with non-small cell lung cancer. Genetic analysis of TMPRSS6 catalytic domain variants in Mexican patients with iron treatment refractoriness.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1